Extended Data Fig. 5: Spatially resolved immune cell landscape of OCCC with and without PPP2R1A mutations.

a-c. The cellular densities of MHC-II⁺ (i.e., HLA-DR⁺) immune cells (a), CD20⁺ B cells (b), and CD20⁺ CD21⁺ B cells (c) in pretreatment samples grouped by PPP2R1A mutation status. d. Representative images from multiplex protein imaging, showing TLSs from the pretreatment samples of PPP2R1A-mutant patients (patient 162 and patient 124. f-g. The cellular densities of all immune cells (f), and CD45⁺ CD56⁺ NK cells (g) in on-treatment samples grouped by PPP2R1A mutation status. h. The amount of PD1⁺ CD8⁺ T cells and CD45RO⁺ PD1^- CD8⁺ T cells in the neighbourhood of MHC I^– tumour cells. The numbers of cells in each group are: 6,520 (PPP2R1A^mut, pre-treatment); 11,226 (PPP2R1A^mut, on-treatment); 17,134 (PPP2R1A^WT, pre-treatment); 63,641 (PPP2R1A^WT, on-treatment). i. The amount of NK cells (CD45⁺ CD4⁻ CD8⁻ CD56⁺) in the neighbourhood of all, MHC I⁺, and MHC I⁻ tumour cells. See the legends of Fig. 3f,g and Extended Data Fig. 5h for cell counts of corresponding groups. j. A representative image from multiplex protein imaging, showing NK cells in the neighbourhood of tumour cells in a PPP2R1A-mutant on-treatment sample. In box plots, the centre line represents the median value; the lower and upper hinges correspond to the first and third quartiles, respectively; the whiskers represent 1.5 × interquartile ranges. For panels a-c and f-i, P values were calculated using two-sided Wilcoxon rank sum tests.